1 (212) 733-4848 Clinical Trials Containment FDA Approval Licensing 
Pfizer
JULY 8, 2022
FDA Approval of their COVID-19 Vaccine COMIRNATY® For Adolescents 12 through 15 Years of Age. FDA Approval of their COVID-19 Vaccine COMIRNATY® For Adolescents 12 through 15 Years of Age. Favorable safety profile observed across more than 2,200 adolescents who participated in the clinical trial.
Pfizer
JULY 19, 2022
1 Adapted Bivalent Vaccine Candidate. 1 Adapted Bivalent Vaccine Candidate. 1 sub-lineage, for individuals 12 years of age and older. 1 as compared to the companies’ current COVID-19 vaccine. A severe allergic reaction would usually occur within a few minutes to 1 hour after getting a dose of the vaccine.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pfizer
JULY 26, 2022
a second booster dose to individuals 50 years of age and older who have received a first booster dose of any authorized or approved COVID-19 vaccine. a second booster dose to individuals 12 years of age and older with certain kinds of immunocompromise and who have received a first booster dose of any authorized or approved COVID-19 vaccine.
Pfizer
JULY 8, 2022
Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are planned. About the Phase 1/2/3 Trial in Children. A severe allergic reaction would usually occur within a few minutes to 1 hour after getting a dose of the vaccine. INTERCHANGEABILITY.
Pfizer
OCTOBER 20, 2022
With more than 26 million adults over the age of 19 who have been previously vaccinated with PREVNAR 13®, today’s ACIP vote recognizes the importance of helping to protect them against the seven additional serotypes contained in PREVNAR 20®,” said Angela Hwang, President, Global Biopharma Business, Pfizer.
Pfizer
NOVEMBER 2, 2022
Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19. Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19. About the Phase 1 Study . Wed, 11/02/2022 - 15:44. INDICATION.
Pfizer
DECEMBER 8, 2022
Pfizer and BioNTech previously announced the start of a Phase 1 trial to examine the safety, tolerability, and immunogenicity of their combined influenza and COVID-19 candidate vaccine among healthy adults. . receipt of the most recent booster dose with any authorized or approved monovalent* COVID-19 vaccine . INDICATION.
Expert insights. Personalized for you.
102 
Let's personalize your content